Results 1 to 10 of about 375 (91)
Zanubrutinib for the Treatment of Lymphoid Malignancies: Current Status and Future Directions
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies.
Anna Wolska-Washer, Tadeusz Robak
exaly +3 more sources
Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor. Its safety and effectiveness in central nervous system (CNS) lymphoma along with its distribution in the brain and ability to cross the blood–brain barrier (BBB) remain unknown. This
Wei Zhang, Chong Wei, Dao-Bin Zhou
exaly +3 more sources
Case Report: Zanubrutinib-Induced Dermatological Toxicities: A Single-Center Experience and Review
Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib.
Lingling Wang +6 more
exaly +3 more sources
Zanubrutinib-Induced Aseptic Meningitis: A Case Report and Literature Review
Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B cell malignancy treatment and is generally well tolerated in most patients. Zanubrutinib-induced aseptic meningitis is currently not reported.
Lian Wang, Chenlu Yang, Jinjun Yang
exaly +3 more sources
Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 ...
Constantine S. Tam +2 more
exaly +2 more sources
Background We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present an updated pooled
Keshu Zhou, Michael Wang, Stephen Opat
exaly +2 more sources
Zanubrutinib is a next‐generation selective Bruton's tyrosine kinase inhibitor (BTKi) with superior efficacy and lower cardiotoxicity rates seen in clinical trials over first‐generation ibrutinib in CLL/SLL patients.
Lisa Law +2 more
exaly +2 more sources
Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be approved, and it changed the standard-of-care treatment for ...
Constantine S. Tam +3 more
doaj +3 more sources
A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures ...
Kun Wang +6 more
doaj +1 more source
Zanubrutinib-induced liver injury: a case report and literature review
Background Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies.
Edmond Atallah +5 more
doaj +1 more source

